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ABSTRACT
Biosimilars are now a reality in rheumatology. Although
analytical and non-clinical procedures to establish
similarity have evolved significantly, clinical trials
demonstrating equivalent efficacy and safety are
absolutely required for all biosimilars. The design of
such trials, including equivalence and non-inferiority
statistical approaches, are discussed. Clinical evidence
on biosimilars that have been approved recently or are
presently being developed for use in rheumatology is
also reviewed and contrasted with that available for
biomimics (or intended copies), which are non-
innovator biologics that are marketed in several
countries but have not undergone review according to
a regulatory pathway for biosimilars.
BACKGROUND
There is now considerable interest in biosimi-
lars among rheumatologists, although the dis-
tinction between a true biosimilar and a
biomimic (or intended copy) may not be clear
to most. Many countries have changed their
regulatory requirements to accommodate this
new class of medicinal products and to distin-
guish them from generics.1 2 Currently, only
one biosimilar is approved by the European
Medicines Agency (EMA) for the treatment of
rheumatological diseases: an inﬂiximab biosi-
milar, which is commercialised as Remsima/
Inﬂectra. Following the lead of the EMA, regu-
latory agencies in other countries, including
South Korea, Canada, Japan, Turkey and
Colombia,3 have approved this inﬂiximab bio-
similar. However, the approved indications
differ among these countries. For example,
EMA allowed the results of clinical trials con-
ducted in rheumatological diseases trials to be
extrapolated to inﬂammatory bowel diseases,
while Health Canada did not.4 Recently,
BOW015, an inﬂiximab biosimilar with the
commercial name Inﬁmab,5 and ZRC-3197, an
adalimumab biosimilar with the commercial
name Exemptia,6 were approved in India,
while HD203, an etanercept biosimilar, was
approved in South Korea.7 Whether other
countries will approve these products with the
data currently available, however, remains to
be seen.
Currently, numerous biosimilars are in
development and it is likely that some of them
will be commercialised in the near future.2
Although analytical and non-clinical proce-
dures to establish similarity have evolved
signiﬁcantly, clinical trials demonstrating
equivalent efﬁcacy and safety are an absolute
requirement for regulatory approval of all bio-
similars.2 8 Understanding the principles by
which these trials are designed and analysed
will help the clinician to evaluate and use
these drugs in practice.
Key messages
What is already known about the subject?
▸ Biosimilars are approved following a regulatory
pathway different to that of generics, as they are
not molecularly identical to their reference pro-
ducts. Thorough information must be provided
on analytical and non-clinical procedures to
show similarity. Moreover, clinical trials demon-
strating equivalent efficacy and safety to the ref-
erence product are absolutely required for all
biosimilars.
What does this study add?
▸ The design of equivalence and non-inferiority
clinical trials is described and discussed. Clinical
evidence available for biosimilars is reviewed
and contrasted to that of biomimics (or intended
copies), which are non-innovator products being
commercialized in some countries without
undergoing review according to a regulatory
pathway for biosimilars.
How might this impact in clinical practice?
▸ Familiarity with issues regarding study design
and methods of analysing data obtained in com-
parative clinical trials allows improving decision
making surrounding the prescription of biosimi-
lars to patients with rheumatic diseases.
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DESIGN OF CLINICAL TRIALS FOR BIOSIMILARITY
Pharmacokinetic studies
Pharmacokinetic comparisons demonstrating equivalence
of certain biosimilars with their corresponding innovators
have been conducted in healthy volunteers and in patients
with rheumatological diseases.9–11 Pharmacokinetic equiva-
lence is necessary, but not sufﬁcient, to demonstrate
biosimilarity.
Biosimilars are not identical to innovators. Certain
molecular differences, albeit minimal, can modify afﬁnity
for the target ligand without modifying pharmacokinet-
ics.2 8 Hence, innovator and non-innovator products may
exhibit differences in clinical efﬁcacy and safety despite
comparable pharmacokinetics. This is why, unlike generic
small molecule drugs, bioequivalence of a biosimilar with
its reference product cannot be established solely on phar-
macokinetic grounds.8 11
Small molecule generics are molecularly identical to the
innovator small molecule drugs, such that all pharmacody-
namic properties of both drugs are exactly the same. The
same is not true of biosimilars with innovator biopharma-
ceuticals.12 Furthermore, a biosimilar and its reference
biopharmaceutical can also differ in terms of immunogen-
icity.8 Thus, at least one clinical study documenting equiva-
lent efﬁcacy and safety is absolutely required.8 12
Equivalence studies
The purpose of a clinical trial comparing a biosimilar to
its innovator is to demonstrate equivalent efﬁcacy and
safety. Therefore, a suitable patient population must be
chosen that is sensitive enough for differences in the
measured end point, which might be due to dissimilar-
ities between the products assayed, to be detected.13 14
The patient groups receiving the innovator and the bio-
similar must be balanced in terms of demographics and
clinical characteristics. The number of subjects studied
should be sufﬁcient to achieve statistical power. Finally,
the primary end point and the study duration must be
clinically relevant.13
Hypothesis tests are designed to demonstrate differ-
ences between two samples and not equivalence.15 In a
comparison performed using a hypothesis test, such as
the Student’s t test or analysis of variance, the absence
of a signiﬁcant difference (ie, p>0.05) does not demon-
strate equivalence. A sample is described by its mean
value and its variability, which is frequently expressed as
the SD. If two samples overlap, it is difﬁcult to demon-
strate a signiﬁcant difference. Overlapping can be due
to a narrow difference between means or to wide SDs.
The SD (s) of a sample is calculated by equation 1,
where x and X are the individual and mean values of
the measured parameter, and n the number of subjects.
S ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃP ðx XÞ2
n 1
s
ð1Þ
If the difference between mean values is the same, over-
lapping depends on the SD values of both samples. This
is shown in ﬁgure 1, where two comparisons are per-
formed where the difference between mean values is the
same in both situations. In ﬁgure 1A, the SD values are
low. Hence, the samples do not overlap and comparison
using a hypothesis test yields a signiﬁcant difference. In
contrast, in ﬁgure 1B, the SD values are high and the
samples thus overlap. In this circumstance, it is not pos-
sible to show a signiﬁcant difference between the two
samples using hypothesis tests.16
Hypothesis tests are used to demonstrate superiority of
one treatment over another and are not valid to demon-
strate equivalence. In equation 1, if n is small, the value
of s is larger. Accordingly, it is impossible to show a sig-
niﬁcant difference between two samples, if the number
of patients to be compared is small, because of high-SD
values.15 16 This, of course, does not imply that the two
samples being compared are equivalent.15 Therefore,
clinical studies with small sample sizes are inadequate to
demonstrate biosimilarity and can be misleading. To
demonstrate that two treatments are equivalent, a clin-
ical trial typically would require a larger sample size
than if it were intended to demonstrate superiority of
one over the other.
Equivalence analysis is less familiar to most clinicians
than is hypothesis testing. However, the principles of
equivalence analysis are not difﬁcult to understand. The
ﬁrst consideration is that equivalence does not imply
identity, but, rather, means that the results observed with
a test product are within a pre-established range in rela-
tion to those obtained with the reference product.13 17
Figure 1 Two comparisons contrasting of two samples each
by hypothesis tests, role of SD values. (A) Comparison of two
samples with low SDs. (B) Comparison of two samples with
wide SDs. In both cases (A and B), the difference between
means is the same.
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The limits of this equivalence range are arbitrary and
are established on the basis of past experience. For a
candidate biosimilar that is being developed to treat
rheumatological diseases, the equivalence range typically
is based on a meta-analysis of placebo-controlled clinical
trials of the reference product. The mean difference in
the outcome measure of interest between the reference
product and placebo is calculated, and then divided by
an arbitrary factor (usually of 2) to narrow the equiva-
lence range.13 Once this range has been established, the
clinical trial comparing the biosimilar to its reference
product is conducted, the observed difference between
treatments is assessed, and the 95% CIs of this differ-
ence are calculated. If these 95% CI are contained
within the pre-established equivalence range, the two
treatments are equivalent.13 17
How is equivalent efﬁcacy determined in practice for a
biosimilar compared to its reference (or innovator)
product? As an example, let us consider the evaluation
of an inﬂiximab biosimilar in comparison to innovator
inﬂiximab (Remicade).13 18 First, a suitable patient
population is chosen (ie, patients with rheumatoid arth-
ritis taking methotrexate). Next, a suitable primary end
point and treatment duration are chosen (ie, percentage
of patients achieving the ACR20 response at week 30).
Finally, an equivalence range is chosen. Since the differ-
ence in the ACR20 response between treatment with
inﬂiximab and placebo is about 30% in the several
placebo-controlled clinical trials of inﬂiximab treatment
for rheumatoid arthritis, an equivalence range of half
that value (15%) is considered to be reasonable. This
means that the ACR20 response to treatment with the
biosimilar can vary by ±15% with respect to that to treat-
ment with the innovator. A logarithmic transformation
of the data is then performed. With log-transformed
data, the ±15% equivalence range is 0.85–1.18, so as to
be symmetrical.
Now, let A and B represent mean values of an efﬁcacy
parameter for the candidate biosimilar and the innov-
ator, respectively. The hypothesis to prove is shown in
equation 2:
0:85  A=B  1:18 ð2Þ
Once A and B have been determined for the two groups
of treated patients studied, A/B is calculated and the
corresponding 95% CIs are estimated. If the 95% CI for
A/B lies entirely within the 0.85–1.18 range, the two
treatments are considered to be equivalent. If this 95%
CI exceeds the lower, higher, or both equivalence limits,
the treatments are not considered to be. This is shown
graphically in ﬁgure 2. White bars depict various 95%
conﬁdence limits for values of A/B that correspond to
equivalence. The mean values can be low or high, and
variability can be small or large. However, as long as the
95% CI lies within the pre-established range, equiva-
lence of the two treatments is established. In each of
these situations, the non-innovator is considered to be
biosimilar to the innovator. Dark bars depict other 95%
CIs for values of A/B that do not meet the deﬁnition of
equivalence. Therefore, the candidate non-innovator
biopharmaceutical cannot be considered to be a biosimi-
lar. In each of these cases, the 95% CI goes beyond the
lower, higher or both equivalence limits. The absolute
magnitude of A/B does not matter when the 95% conﬁ-
dence limit exceeds either the lower or upper limit of
the pre-established range. In that situation, equivalence
cannot be established and the candidate non-innovator
biopharmaceutical tested is considered to not be biosi-
milar to the reference product.17
The inﬂiximab biosimilar CT-P13 showed efﬁcacy
equivalent to that of innovator inﬂiximab (Remicade) in
the PLANETRA study.18 In this study, 606 patients with
rheumatoid arthritis, inadequately responsive to metho-
trexate, were randomised 1:1 to receive either CT-P13 or
innovator inﬂiximab. The primary efﬁcacy outcome was
the proportion of subjects achieving an ACR20 response
at 30 weeks. At this time point, the response rates for the
biosimilar and the innovator were 60.9% (184/302) and
58.9% (178/304), respectively, in the intention-to-treat
population. The difference between treatments was 2%
with a CI 95% of −6% to 10%. Since the entirety of this
CI lies within the pre-established range of ±15% (0.85–
1.18 after logarithmic transformation), the efﬁcacy of
CT-P13 was considered to be equivalent to that of innov-
ator inﬂiximab. A similar ﬁnding was observed in the
per protocol analysis, where the response rates for the
Figure 2 Graphical
representation of equivalence
analyses. (A and B) are the
efficacy parameters of biosimilar
and innovator, respectively. Bars
correspond to the 95% CIs of
A/B. Equivalence is declared
when the entirety of the 95% CI is
comprised within the equivalence
interval (white bars). Equivalence
cannot be declared when the
95% CI goes beyond the inferior,
the superior or both equivalence
limits (black bars).
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biosimilar and the innovator were 73.4% (182/248) and
69.7% (175/251), respectively. The difference between
treatments in this analysis was 4%, with a 95% CI of
−4% to 12%. Since this 95% CI also lies entirely within
the pre-established range of ±15%, the two treatments
again were considered to be equivalent.
Non-inferiority approach
In some circumstances, a non-inferiority approach can
be suitable to evaluate biosimilarity.17 19 The guidelines
on biosimilar evaluation issued by the WHO consider a
non-inferiority design to be acceptable.20 Accordingly,
several countries will accept such a non-inferiority
approach. In Canada, regulatory authorities have
acknowledged that an equivalence trial design is pre-
ferred. However, if clearly justiﬁed, a non-inferiority
approach may be acceptable under certain conditions.
Evidence must be provided that an eventual superiority
has no clinical meaning and that there is no increase in
adverse reactions with regard to the reference product.21
In comparative effectiveness clinical trials designed
using a non-inferiority approach, the test product can be
superior to the reference product but it cannot be infer-
ior. If a biosimilar is to be compared to an innovator
using a non-inferiority approach, the hypothesis to be
proven is shown in equation 3:
0:85  A=B ð3Þ
In this situation, all of the 95% CI for log-transformed data
must be above the inferiority limit. However, here there is
no superiority limit. Examples of this are depicted in
ﬁgure 3. White bars represent 95% CIs for values of A/B
that correspond to non-inferiority. The results may be
close to or far above the inferiority limit and variability can
be small or large. However, as long as the inferiority limit
is not exceeded, the biosimilar is considered to be non-
inferior to the reference product. Alternatively, the dark
bars represent values of A/B that do not meet the deﬁn-
ition of non-inferiority, since the 95% CIs for these values
of A/B go below the inferiority limit, regardless of
whether or not variability is low or high.
The non-inferiority approach has the advantage of
requiring fewer patients to achieve statistical power.17 19
However, it is not adequate to assess biosimilarity of bio-
pharmaecuticals used to treat rheumatological diseases,
since it does not detect the situation in which a non-
innovator is superior to the reference product and thus
is bio-better and not biosimilar. A bio-better that pro-
duces a greater pharmacological response in some
patients might have not only superior efﬁcacy, but also
increased toxicity.8 To date, no biosimilar has been
approved using a non-inferiority approach to compare
effectiveness to its reference product.
OTHER BIOSIMILARS
Presently, only one biosimilar has been approved by the
EMA for use in rheumatology: the biosimilar inﬂiximab
CT-P13 (Remsima/Inﬂectra).2 This biosimilar monoclo-
nal antibody has also been approved in Canada, Japan,
Turkey, Colombia and South Korea,3 although with dif-
ferences in the indications for which it has been
authorised.4 CT-P13 has been submitted for review by
the US Food and Drug Administration (FDA).3 There is
worldwide interest regarding how the US FDA will con-
sider this biosimilar. Will full extrapolation of indications
be granted? Will additional clinical studies be requested?
Such questions will soon be answered when the US FDA
makes public its ﬁndings.
Other biosimilars to treat rheumatological diseases,
including inﬂiximab, adalimumab and etanercept, have
been approved recently in India and South Korea.5–7
Other biosimilars are under development, many of
which have been tested in clinical trials, and likely will
reach the market over the coming years.2
The results of several trials of biosimilars in rheumato-
logical diseases have been presented at major inter-
national rheumatology meetings. Bae et al22 compared
an etanercept biosimilar, HD203, with innovator etaner-
cept, Enbrel, in South Korean patients with rheumatoid
arthritis inadequately responsive to methotrexate. A total
of 294 patients were randomised 1:1 to receive either
HD203 or innovator etanercept, each in combination
with methotrexate. The primary end point was the pro-
portion of patients achieving ACR20 response at week
24. Patients also were assessed at week 48. The differ-
ence in the ACR20 response rate between patients
Figure 3 Graphical
representation of non-inferiority
analyses. (A and B) are the
efficacy parameters of biosimilar
and innovator, respectively. Bars
correspond to the 95% CIs of
A/B. Non-inferiority is declared
when the entirety of the 95% CI
lies above the inferiority limit
(white bars). Non-inferiority
cannot be declared when the
95% CI goes beyond the
inferiority limit.
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treated with HD203 and innovator etanercept was 2.12%
with a 95% CI of −7.65% to 11.89% after 24 weeks, and
was 4.37% with a CI of −5.57% to 14.31% after
48 weeks. Equivalence was concluded, although the pub-
lished abstract did not disclose the pre-established
equivalence range. On the basis of this trial, HD203 was
approved in South Korea.7 Whether regulatory agencies
in other countries will request additional information
before approving this biosimilar etanercept remains to
be seen.
Kay and coworkers compared BOW015, an inﬂiximab
biosimilar, with innovator inﬂiximab (Remicade) in
patients with rheumatoid arthritis inadequately respon-
sive to methotrexate. A total of 189 patients were rando-
mised 2:1 to receive BOW015 or innovator inﬂiximab.
The primary end point was the proportion of patients
achieving an ACR20 response at week 16, with an equiva-
lence margin of±23%. Data have been reported through
54 weeks.23 24 The differences in the ACR20, ACR50 and
ACR70 response rates between patients treated with
BOW015 and innovator inﬂiximab were within this
equivalence range, both by intention-to-treat and per
protocol analysis. Furthermore, both biopharmaceuticals
exhibited similar kinetics of these responses at several
time points before the plateau phase of the time-
response curve. The authors concluded therapeutic
equivalence and BOW015 was recently approved as a
biosimilar in India on the basis of this clinical trial.5
Whether other countries will grant approval to BOW015
as an inﬂiximab biosimilar with the presently available
clinical trial data remains to be seen.
As is evident, there is no standardised clinical assay for
biosimilarity in rheumatological diseases at present. To
date, studies of biosimilars to treat rheumatoid arthritis
have used the ACR20 response as the primary end point.
However, these clinical trials vary in their randomisation
strategies, equivalence ranges and duration of treatment.
Since additional biosimilars are being developed, the
design of clinical trials to gain regulatory approval
should be standardised.
BIOMIMICS OR INTENDED COPIES
Biomimics, also known as intended copies, are non-
innovator biologics that had received marketing approval
before biosimilar regulations were put in place. They cur-
rently are available in some Asian and Latin American
countries. Biomimics cannot be considered to be biosimi-
lars, since they have not been subjected to review by an
appropriate regulatory body according to a prespeciﬁed
regulatory pathway for biosimilar approval.25 Limited and
ﬂawed clinical information is available regarding biomi-
mics used to treat rheumatological diseases.
Yisaipu is an etanercept biomimic that is manufac-
tured and marketed in China. It is also commercialised
as Etanar in Colombia, as Etart in Mexico and as
Etacept in India.2 8 12 25 26 Clinical experience in China
has found Yisaipu to be effective.26 However, it is
surprising that, despite this product having been used in
China for over a decade, no data have been published
about drug survival or on the incidence of tuberculosis
and other adverse effects. Furthermore, no head-to-head
studies have been conducted to comparing Yisaipu to
innovator etanercept. Thus, this product cannot be con-
sidered to be an etanercept biosimilar. An abstract
describing an open-label study of Etanar treatment in
110 patients with rheumatoid arthritis was presented at
the 2010 ACR Annual Scientiﬁc meeting.27 The patients
enrolled were receiving a variety of antirheumatic drug
regimens concomitantly with Etanar. The number of
patients studied was small, considering the variety of
treatment regimens that were allowed. Etanar was not
compared to innovator etanercept.
Inﬁnitam is a non-innovator etanercept that is manu-
factured and marketed by the Mexican company,
Probiomed.25 An abstract describing a study comparing
Inﬁnitam to innovator etanercept (Enbrel) was pre-
sented in the 2013 EULAR Annual Scientiﬁc meeting.28
The design of this study is confusing. Three groups of
patients were studied. In the ﬁrst group, 12 patients
received Inﬁnitam and methotrexate for 24 weeks. In
the second group, 12 patients initially received Inﬁnitam
and methotrexate for 12 weeks, followed by innovator
etanercept and methotrexate for the subsequent
12 weeks. Patients in these two groups were participating
in a pharmacokinetic study. In the third group, 30
patients received Inﬁnitam and methotrexate for
24 weeks. End points were DAS28 at weeks 12 and 24,
but a primary end point was not speciﬁed. The authors
stated that DAS28 improved and that drug safety was
similar in all treatment groups. However, it appears that
only patients enrolled in the ﬁrst and third groups
received the same treatment regimen. The only distinction
between these groups was that patients in the ﬁrst group
were participating in a pharmacokinetic study, whereas
those in the third group were not. The authors concluded
that “none [sic] signiﬁcant difference was observed in the
pharmacokinetic groups (p=0.355)”. As mentioned
earlier, failure to detect a signiﬁcant difference is evidence
of neither equivalence nor of biosimilarity. This is particu-
larly true when the sample size is evidently small
(12 patients per group), yielding high-SD values. Thus,
based on this study, Inﬁnitam cannot be considered to be
an etanercept biosimilar. Whereas the primary reason for
a biosimilar to be used instead of the innovator is its lower
price, the cost of this biomimic in some acquisition con-
tracts by the Social Security in Mexico has been the same
as that of innovator etanercept.25
As can be appreciated, there is an enormous differ-
ence in quality between the studies described in the
abstracts about the biosimilars HD203 and BOW015,
and those about the biomimics Etanar and Inﬁnitam.
The data on HD203 and BOW015 likely will be pub-
lished in peer-reviewed journals in the near future,
allowing readers to assess the advantages as well as the
limitations of these biosimilars. On the other hand, no
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peer-reviewed publication documents the efﬁcacy or
safety of Yisaipu/Etanar/Etart or of Inﬁnitam, despite
these products having been available and used to treat
patients with rheumatological diseases in several coun-
tries for several years.
Kikuzubam is a rituximab biomimic that was manufac-
tured and marketed in Mexico by Probiomed.2 8 25 In
2012, the Mexican programme of Pharmacovigilance
issued a communication to health professionals warning
them of anaphylactic reactions that occurred in several
patients who were switched from innovator rituximab
(Mabthera) to the biomimic, or vice versa.29 This was
surprising, since innovator rituximab had exhibited a
very favourable peri-infusion safety proﬁle among
Mexican patients.30 Owing to these anaphylactic reac-
tions and the lack of clinical data documenting the efﬁ-
cacy and safety of Kikuzubam, approval to market
Kikuzubam in Mexico was withdrawn by the regulatory
authority on 28 March 2014.31
Reditux is a rituximab biomimic manufactured in India
and marketed in India and in several Latin American
countries.2 8 To the best of our knowledge, no clinical
trial has been performed to demonstrate equivalent efﬁ-
cacy and safety of Reditux with innovator rituximab
(Mabthera) in patients with a rheumatological disease.
However, analytical studies have demonstrated signiﬁcant
differences in physicochemical properties between
Reditux and innovator rituximab.32 Thus, Reditux
cannot be considered to be a rituximab biosimilar.
CONCLUDING REMARKS
True biosimilars should not be confused with biomimics
that have not undergone rigorous clinical testing or regu-
latory review according to a pathway for approval of biosi-
milars. There are only two options for biomimics: either
document their efﬁcacy and safety in well-designed com-
parative effectiveness clinical trials, and subject them to
regulatory review so that they can become true biosimi-
lars, or remove them from the market altogether.
The perception of biosimilars in rheumatology has
evolved over the past several years. Distrust about the use
of biosimilars in clinical practice has waned as regulatory
pathways have been implemented and applied to the
approval of a biosimilar inﬂiximab. Although analytical
and non-clinical evidence plays a considerable role, clin-
ical trials that demonstrate comparable efﬁcacy and
safety of the biosimilar with its reference product are of
paramount importance to establish biosimilarity.
Familiarity of clinicians with issues regarding study
design and the methods of analysing data obtained in
comparative effectiveness clinical trials undoubtedly will
improve decision-making surrounding the prescription
of biosimilars to patients with rheumatological diseases.
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